Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
22
01
2019
accepted:
29
01
2019
pubmed:
27
2
2019
medline:
27
2
2019
entrez:
27
2
2019
Statut:
ppublish
Résumé
The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.
Identifiants
pubmed: 30807997
pii: S1936-5233(19)30033-6
doi: 10.1016/j.tranon.2019.01.007
pmc: PMC6393699
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
640-645Informations de copyright
Published by Elsevier Inc.
Références
Clin Cancer Res. 2005 Feb 15;11(4):1669-74
pubmed: 15746072
J Clin Oncol. 2005 Sep 1;23(25):6207-19
pubmed: 16135488
Radiology. 2007 Mar;242(3):882-8
pubmed: 17229875
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
J Thorac Oncol. 2010 Jan;5(1):110-6
pubmed: 20035187
Eur Respir J. 2011 Mar;37(3):624-31
pubmed: 20595147
Clin Cancer Res. 2010 Dec 1;16(23):5873-82
pubmed: 21030498
Ann Oncol. 2011 Nov;22(11):2466-70
pubmed: 21321089
Radiat Oncol. 2011 Nov 25;6:166
pubmed: 22118497
Prog Neurol Surg. 2012;25:110-4
pubmed: 22236672
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Lung Cancer. 2012 Sep;77(3):556-60
pubmed: 22677429
Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405
pubmed: 22806307
J Neurooncol. 2013 Apr;112(2):247-55
pubmed: 23354655
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Curr Oncol. 2013 Aug;20(4):e300-6
pubmed: 23904768
J Thorac Oncol. 2014 Feb;9(2):195-9
pubmed: 24419416
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
J Thorac Oncol. 2015 Jan;10(1):156-63
pubmed: 25247337
Chemother Res Pract. 2014;2014:856156
pubmed: 25548673
J Chemother. 2015 Aug;27(4):221-6
pubmed: 25735792
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
J Thorac Oncol. 2015 Sep;10(9):1268-1278
pubmed: 26107553
J Clin Oncol. 2015 Oct 20;33(30):3488-515
pubmed: 26324367
Oncotarget. 2016 Jan 26;7(4):3847-56
pubmed: 26716903
Drugs. 2016 Feb;76(2):263-73
pubmed: 26729184
J Thorac Oncol. 2016 Mar;11(3):380-90
pubmed: 26823294
Lung Cancer. 2016 Jun;96:101-7
pubmed: 27133758
Clin Drug Investig. 2016 Aug;36(8):683-6
pubmed: 27177916
Mol Cancer Ther. 2016 Aug;15(8):1845-58
pubmed: 27196753
J Thorac Oncol. 2016 Oct;11(10):1718-28
pubmed: 27237825
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
Oncol Res Treat. 2016;39(7-8):461-3
pubmed: 27486808
Clin Cancer Res. 2017 May 1;23(9):2131-2135
pubmed: 27923840
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Cancer Res. 2017 Mar 1;77(5):1200-1211
pubmed: 28082405
Medicine (Baltimore). 2017 Feb;96(6):e6087
pubmed: 28178168
J Clin Oncol. 2017 Apr 20;35(12):1288-1296
pubmed: 28221867
Clin Lung Cancer. 2018 Jan;19(1):e1-e3
pubmed: 28668204
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
J Thorac Dis. 2017 Aug;9(8):2510-2520
pubmed: 28932557
Onco Targets Ther. 2017 Nov 03;10:5281-5288
pubmed: 29138581
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Ann Oncol. 2018 Mar 1;29(3):687-693
pubmed: 29293889
Clin Cancer Res. 2018 Jun 1;24(11):2594-2604
pubmed: 29298799
Mol Clin Oncol. 2018 Feb;8(2):246-249
pubmed: 29399354
Cancer Lett. 2018 Jun 1;423:9-15
pubmed: 29524556
Clin Cancer Res. 2018 Oct 15;24(20):5112-5122
pubmed: 29967253
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Oncologist. 2018 Aug 20;:null
pubmed: 30126856
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097